Yousif Capital Management LLC Purchases 1,837 Shares of ADMA Biologics Inc $ADMA

Yousif Capital Management LLC lifted its position in ADMA Biologics Inc (NASDAQ:ADMA) by 2.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 91,095 shares of the biotechnology company’s stock after acquiring an additional 1,837 shares during the quarter. Yousif Capital Management LLC’s holdings in ADMA Biologics were worth $1,659,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ADMA. Nuveen LLC bought a new stake in shares of ADMA Biologics in the first quarter worth about $93,543,000. Vaughan Nelson Investment Management L.P. bought a new stake in shares of ADMA Biologics in the second quarter worth about $32,786,000. Driehaus Capital Management LLC increased its holdings in shares of ADMA Biologics by 114.9% in the first quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock worth $58,460,000 after purchasing an additional 1,575,363 shares during the last quarter. Invesco Ltd. increased its holdings in shares of ADMA Biologics by 13.9% in the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock worth $255,279,000 after purchasing an additional 1,570,649 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of ADMA Biologics by 152.7% in the first quarter. Russell Investments Group Ltd. now owns 1,632,675 shares of the biotechnology company’s stock worth $32,392,000 after purchasing an additional 986,666 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Trading Down 1.4%

Shares of NASDAQ ADMA opened at $14.36 on Monday. The business’s 50 day moving average is $16.00 and its two-hundred day moving average is $18.36. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The stock has a market capitalization of $3.43 billion, a P/E ratio of 16.70 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company had revenue of $121.98 million for the quarter, compared to analysts’ expectations of $121.77 million. During the same period in the previous year, the firm posted $0.13 earnings per share. The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. As a group, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of ADMA Biologics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to data from MarketBeat, ADMA Biologics currently has an average rating of “Buy” and a consensus target price of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.